Intensity Therapeutics (INTS) Accounts Payables (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Accounts Payables came in at $636000.0 in Q1 2026, down 59.9% YoY from $1.6 million in Q1 2025, and up 9.09% on a QoQ basis from $583000.0 in Q4 2025.
Intensity Therapeutics (INTS) Accounts Payables (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Accounts Payables data on file, last reported at $636000.0 in Q1 2026.
- Quarterly Accounts Payables fell 59.9% year-over-year to $636000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636000.0 (down 59.9% YoY) and the FY2025 annual result came in at $583000.0, down 52.17% from the prior year.
- Accounts Payables grew to $636000.0 in Q1 2026, from $583000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $3.0 million in Q4 2023 to a low of $358404.0 in Q3 2023.
- A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 405.47% — and 2024, when it plunged 60.01%.
- Tracing INTS's Accounts Payables over 5 years: stood at $603000.0 in 2022, then jumped by 405.47% to $3.0 million in 2023, then sank by 60.01% to $1.2 million in 2024, then plunged by 52.17% to $583000.0 in 2025, then increased by 9.09% to $636000.0 in 2026.
- The last three Accounts Payables figures came in at $636000.0 (Q1 2026), $583000.0 (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 35.57 Mn |
| 10 | Intensity Therapeutics | 12.80 Mn | 12.80 Mn | - | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Mn |
| Mar 31, 2026 | 636,000.00 |
| Dec 31, 2025 | 583,000.00 |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 540,000.00 |
| Jun 30, 2024 | 1.92 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | 358,404.00 |
| Jun 30, 2023 | 1.58 Mn |
| Dec 31, 2022 | 603,000.00 |